Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults

Archives of Neurology

Volumn 64, Issue 3, 2007, Pages 343-349

  Fagan, Anne M ^a   Roe, Catherine M ^a   Xiong, Chengjie ^a   Mintun, Mark A ^a,b   Morris, John C ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COMMUNITY CARE; CONTROLLED STUDY; DEMENTIA; ELDERLY CARE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MENTAL DETERIORATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SCREENING;

AGED; AGED, 80 AND OVER; AGING; AMYLOID BETA-PROTEIN; CHI-SQUARE DISTRIBUTION; COGNITION DISORDERS; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 33947223454     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.3.noc60123     Document Type: Article

References (24)

1. Price J, Ko A, Wade M, Tsou S, McKeel D, Morris J. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol. 2001;58:1395-1402.
2. Gomez-Isla T, Price JL, McKeel DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-4500.
3. Morris J, Price J. Pathologic correlates of nondemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci. 2001;17:101-118.
4. Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol. 1998;57:1168-1174.
5. Markesbery W, Schmitt F, Kryscio R, Davis D, Smith C, Wekstein D. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006;63:38-46.
6. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA. 2003;289:2094-2103.
7. 42 in humans. Ann Neurol. 2006;59:512-519.
8. Klunk W, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319.
9. Morris J, McKeel D, Fulling K, Torack R, Berg L. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol. 1988;24:17-22.
10. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol. 1998;55:326-335.
11. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
13. Fagan A, Younkin L, Morris J, et al. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol. 2000;48:201-210.
14. Cirrito J, May P, O'Dell M, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci. 2003;23:8844-8853.
15. Roses A. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med. 1996;47:387-400.
16. Peskind E, Li G, Shofer J, et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006;63:936-939.
17. Mehta P, Pirttila T, Patrick B, Barshatzky M, Mehta S. Amyloid β protein 1-40 and 1-42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease. Neurosci Lett. 2001;304:102-106.
18. Hampel H, Teipel S, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9:705-710.
19. Herukka S, Hallikainen M, Soininen H, Pirttila T. CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64:1294-1297.
20. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006;5:228-234.
21. Andersen K, Launer LJ, Dewey ME, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies. Neurology. 1999;53:1992-1997.
22. Stern Y, Gurland B, Tatemichi T, Tang M, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994;271:1004-1010.
23. Mortimer J, Snowdon D, Markesbery W. Head circumference, education, and risk of dementia: findings from the Nun Study. J Clin Exp Neuropsychol. 2003;25:671-679.
24. Coats M, Morris J. Antecedent biomarkers of Alzheimer's disease: the adult children study. J Geriatr Psychiatry Neurol. 2005;18:242-244.